Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study

The Lancet Oncology 2026

View at publisher
Authors: Timo F W Soeterik, Marcin Miszczyk, Max Peters, Mateusz Bilski, Giulio Francolini, Pietro Garlatti, Luca Nicosia, Filippo Alongi, M. Mežeckis, Justyna Kociolek, Carlo Greco, Tomasz Techmański
+10 more Eline H. Huele, Frederik R. Teunissen, Paulien G Westhoff, Wessel Vis, Marie A D Haverkort, Jochem R N Van Der Voort Van Zyp, Martijn P W Intven, Joanne M van der Velden, Shahrokh F Shariat, Wietse S.C. Eppinga
DOI: 10.1016/s1470-2045(25)00717-x
Cited by: 4
References: 26

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
3
Pages
383–392
Publication date
16 February 2026
Language
EN